目的:分析支气管动脉化疗灌注与栓塞相结合的治疗方式对晚期肺癌患者(体能状态评分大于或等于2分(Performance Status Score≥2,PS≥2))的临床效果。方法:本研究纳入2020年5月至2021年10月期间到本院接受治疗的100例晚期肺癌患者(PS≥2...目的:分析支气管动脉化疗灌注与栓塞相结合的治疗方式对晚期肺癌患者(体能状态评分大于或等于2分(Performance Status Score≥2,PS≥2))的临床效果。方法:本研究纳入2020年5月至2021年10月期间到本院接受治疗的100例晚期肺癌患者(PS≥2分),按照治疗方法将其分为:对照组(n=42)采用静脉化疗,具体用药为吉西他滨(1000 mg•m^(-2),第1天和第8天)和顺铂(75 mg•m^(-2),第1天),每1个月为一个治疗周期;观察组(n=100)采用支气管动脉灌注化疗与栓塞术联合治疗,化疗药物剂量及用法与对照组一致,在完成化疗药物灌注后使用聚乙烯醇颗粒作为栓塞剂阻断肿瘤血供。两组患者均在治疗前及治疗4个月后采用化学发光免疫分析法测定血清CEA和CA125水平对比疗效、CEA和CA125水平,以及不良反应发生水平情况,1年、2年以及3年的生存率。结果:治疗6周后,相较于对照组,观察组疗效较高(P<0.05);在CEA、CA125水平方面,治疗4个月后两组CEA、CA125水平均显著降低且观察组水平均低于对照组(P<0.05);两组均经过为期3年的随访,观察组1年、2年以及3年的生存率均较对照组高(P<0.05);治疗4个月后,相较于对照组,观察组不良反应发生率较低(P<0.05)。结论:支气管动脉灌注化疗联合栓塞术对PS≥2分晚期肺癌患者具有更好的临床效果,能够在降低肿瘤标志物水平的同时提高生存率,并降低不良反应的发生风险,因此,值得在临床中推广应用。展开更多
This article discusses the evolving real-world practice using nitazoxanide,nonsteroidal anti-inflammatory drugs(NSAIDs)and/or azithromycin(Kelleni’s protocol)to manage the evolving manifestations of severe acute resp...This article discusses the evolving real-world practice using nitazoxanide,nonsteroidal anti-inflammatory drugs(NSAIDs)and/or azithromycin(Kelleni’s protocol)to manage the evolving manifestations of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)Omicron EG.5.1,its descendant HV.1 as well as BA.2.86 and its descendant JN.1 subvariants in Egypt in 2024.These subvariants are well-known for their highly evolved immune-evasive properties and the manifestations include some peculiar manifestations as persistent cough besides high fever in young children as well as high fever,persistent severe cough,change of voice,loss of taste and smell,epigastric pain,nausea,vomiting,diarrhea,generalized malaise and marked bone aches in adults including the high-risk groups.It’s suggested that the ongoing SARS-CoV-2 evolution is continuing to mostly affect the high-risk groups of patients,to some of whom we’ve also successfully prescribed nitazoxanide and/or NSAIDs for post-exposure prophylaxis of all household contacts.We also continue to recommend starting the immune-modulatory antiviral Kelleni’s protocol as soon as possible in the course of infection and adjusting it in a personalized manner to be more aggressive from the beginning for the high risk patients,at least until the currently encountered surge of infections subsides.展开更多
文摘目的:分析支气管动脉化疗灌注与栓塞相结合的治疗方式对晚期肺癌患者(体能状态评分大于或等于2分(Performance Status Score≥2,PS≥2))的临床效果。方法:本研究纳入2020年5月至2021年10月期间到本院接受治疗的100例晚期肺癌患者(PS≥2分),按照治疗方法将其分为:对照组(n=42)采用静脉化疗,具体用药为吉西他滨(1000 mg•m^(-2),第1天和第8天)和顺铂(75 mg•m^(-2),第1天),每1个月为一个治疗周期;观察组(n=100)采用支气管动脉灌注化疗与栓塞术联合治疗,化疗药物剂量及用法与对照组一致,在完成化疗药物灌注后使用聚乙烯醇颗粒作为栓塞剂阻断肿瘤血供。两组患者均在治疗前及治疗4个月后采用化学发光免疫分析法测定血清CEA和CA125水平对比疗效、CEA和CA125水平,以及不良反应发生水平情况,1年、2年以及3年的生存率。结果:治疗6周后,相较于对照组,观察组疗效较高(P<0.05);在CEA、CA125水平方面,治疗4个月后两组CEA、CA125水平均显著降低且观察组水平均低于对照组(P<0.05);两组均经过为期3年的随访,观察组1年、2年以及3年的生存率均较对照组高(P<0.05);治疗4个月后,相较于对照组,观察组不良反应发生率较低(P<0.05)。结论:支气管动脉灌注化疗联合栓塞术对PS≥2分晚期肺癌患者具有更好的临床效果,能够在降低肿瘤标志物水平的同时提高生存率,并降低不良反应的发生风险,因此,值得在临床中推广应用。
文摘This article discusses the evolving real-world practice using nitazoxanide,nonsteroidal anti-inflammatory drugs(NSAIDs)and/or azithromycin(Kelleni’s protocol)to manage the evolving manifestations of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)Omicron EG.5.1,its descendant HV.1 as well as BA.2.86 and its descendant JN.1 subvariants in Egypt in 2024.These subvariants are well-known for their highly evolved immune-evasive properties and the manifestations include some peculiar manifestations as persistent cough besides high fever in young children as well as high fever,persistent severe cough,change of voice,loss of taste and smell,epigastric pain,nausea,vomiting,diarrhea,generalized malaise and marked bone aches in adults including the high-risk groups.It’s suggested that the ongoing SARS-CoV-2 evolution is continuing to mostly affect the high-risk groups of patients,to some of whom we’ve also successfully prescribed nitazoxanide and/or NSAIDs for post-exposure prophylaxis of all household contacts.We also continue to recommend starting the immune-modulatory antiviral Kelleni’s protocol as soon as possible in the course of infection and adjusting it in a personalized manner to be more aggressive from the beginning for the high risk patients,at least until the currently encountered surge of infections subsides.
